First Collaborative Definition of Patient Centricity, Co-created by AstraZeneca with Patients and Carers, Is Published in British Medical Journal
AstraZeneca today announced that BMJ Innovations has published the first collaborative definition of patient centricity for the pharmaceutical industry. The definition was co-developed with patients and caregivers using research led by AstraZeneca and patient community advocates to ensure a deep understanding of patient needs and values. Ten associated patient-centric principles were also identified and published in BMJ Innovations to provide the pharmaceutical industry with a consistent reference point to sustain meaningful and mutually beneficial engagement with patients. Wider testing of these outputs among US and European patient communities confirmed their validity.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170331005036/en/
The research published in BMJ defines patient centricity as: “Putting the patient first in an open and sustained engagement of the patient to respectfully and compassionately achieve the best experience and outcome for that person and their family.” This definition encompassed five clear points of importance to patients that were identified and validated through the research: (1) inclusiveness; (2) sharing goals that are patient and family centred; (3) empowering patients to take control of their own health; (4) working in a way that shows respect, compassion and openness; and (5) working in partnership.
Patricia Furlong, President and CEO of Parent Project Muscular Dystrophy and a co-author of the research, said: “This is a landmark project for the pharmaceutical industry. As patients and caregivers, we are eager to see industry engaging with patients in a meaningful way to deliver what we actually want. This definition and set of guiding principles creates a clear signpost for industry by establishing a goal for how to meaningfully put patients at the centre of work by involving them in decision-making in a way that truly benefits them.”
Guy Yeoman, Vice President, Patient Centricity at AstraZeneca, said: “We asked patients what they wanted our industry to focus on, and we heard very clearly that they wanted us to stop concentrating solely on what we deliver, and think about how we deliver it. If we get the ‘how’ right, then the ‘what’ will be so much more meaningful and impactful for patients. For the first time, we believe we have a definitive direction for how patient engagement should be conducted in the way we, as an industry, research and develop our medicines”.
AstraZeneca’s research included extensive engagement with patients, including interviews with individual patients and patient organisations, and interaction with patients through an online forum and patient advisory boards. Healthcare providers and payers also provided input on patient needs. Following the data collection, researchers conducted two patient workshops designed to develop a definition of patient centricity and identify relevant principles for pharmaceutical companies that are most important to patients. Developed by a total of 22 patients and caregivers across a wide variety of conditions from North America and Europe, the principles were also validated via 470 and 703 patients in the PatientsLikeMe and Carenity online networks, respectively.
Reference: Yeoman G, Furlong P, Seres M, et al. Defining patient centricity with patients for patients and caregivers: a collaborative endeavor. BMJ Innovations Published Online First: 24 March 2017. doi: 10.1136/bmjinnov-2016-000157
NOTES TO EDITORS
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
This press release is issued from AstraZeneca Corporate Headquarters in Cambridge, UK and is intended to provide information about our global business. Please be aware that any information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where AstraZeneca conducts business.
+44 776 656 5798
+44 203 749 5821
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
LOXAM20.7.2018 16:53 | pressemeddelelse
Loxam Announces a Conditional Agreement to Acquire UK Platforms
SCHLUMBERGER-LIMITED20.7.2018 13:02 | pressemeddelelse
Schlumberger Announces Second-Quarter 2018 Results
FL-H.I.G.-CAPITAL19.7.2018 21:52 | pressemeddelelse
H.I.G. Capital Announces the Sale of KidsFoundation
SIG-COMBIBLOC-GROUP19.7.2018 18:03 | pressemeddelelse
SIG Combibloc Group Holdings S.à r.l.: 2018 Second Quarter Results
FL-NEORIS19.7.2018 17:34 | pressemeddelelse
NEORIS Announces Creation of Innovation Labs Worldwide to Create a Smarter Future
CQN-FLEXTRADE19.7.2018 17:31 | pressemeddelelse
CORRECTING and REPLACING Albar Capital Deploys FlexNOW
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum